Why has patient adherence to Merck's Januvia diabetes medication dropped by 12% since the launch of the new formulation?

Introduction

The recent 12% drop in patient adherence to Merck's Januvia diabetes medication following the launch of a new formulation is a critical issue that demands immediate attention. This analysis will systematically investigate potential root causes, generate data-driven hypotheses, and propose a strategic plan to address the adherence decline.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking the new formulation might have unexpected side effects. Have there been any changes in reported side effects or adverse events since the launch?

Why it matters: Side effects directly impact patient adherence. Expected answer: Slight increase in mild gastrointestinal issues reported. Impact on approach: If confirmed, we'd focus on formulation adjustments and patient education.

• Considering patient demographics, I'm wondering if the adherence drop is uniform across all age groups. Can you provide a breakdown of adherence rates by patient age segments?

Why it matters: Different age groups may have varying responses to the new formulation. Expected answer: Adherence drop more pronounced in older patients (65+). Impact on approach: We'd tailor interventions for specific age groups if disparities exist.

• Thinking about the healthcare ecosystem, has there been any change in insurance coverage or copay amounts for Januvia since the new formulation launch?

Why it matters: Financial factors significantly influence medication adherence. Expected answer: No major changes in coverage or copay amounts. Impact on approach: If changes occurred, we'd need to address affordability and access issues.

• Considering the competitive landscape, have any new diabetes medications entered the market around the same time as the new Januvia formulation?

Why it matters: New alternatives could impact patient choices and adherence. Expected answer: One new competitor launched a similar medication two months ago. Impact on approach: We'd need to assess Januvia's positioning and value proposition relative to new options.